Merck and Daiichi Sankyo Strike Cancer Drug Deal Worth Up to $22 Billion
Merck agreed to pay Daiichi Sankyo $5.5 billion for the rights to jointly develop and commercialize three of its candidate cancer drugs, in a deal that could be worth up to $22 billion depending on the treatments' success.
Merck agreed to pay Daiichi Sankyo $5.5 billion for the rights to jointly develop and commercialize three of its candidate cancer drugs, in a deal that could be worth up to $22 billion depending on the treatments' success.
:max_bytes(150000):strip_icc()/GettyImages-135787937-9497b16243844095917d45f3ab9ddc8f.jpg){kind=small}
/Primary_Image-4dde2e1352424e1abcb4ca374dd52801.jpg){kind=small}
:max_bytes(150000):strip_icc()/GettyImages-1351333930-c16be1d0252a4a798f08cfb753f744fb.jpg){kind=small}
